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Abstract: The potency, selectivity, and decreased side effects of bioactive peptides have
propelled these agents to the forefront of pharmacological research. Peptides are especially
promising for the treatment of neurological disorders and pain. However, delivery of
peptide therapeutics often requires invasive techniques, which is a major obstacle to their
widespread application. We have developed a tailored peptide drug delivery system in
which the viral capsid of P22 bacteriophage is modified to serve as a tunable nanocontainer
for the packaging and controlled release of bioactive peptides. Recent efforts have
demonstrated that P22 nanocontainers can effectively encapsulate analgesic peptides and
translocate them across blood-brain-barrier (BBB) models. However, release of
encapsulated peptides at their target site remains a challenge. Here a Ring Opening
Metathesis Polymerization (ROMP) reaction is applied to trigger P22 nanocontainer
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disassembly under physiological conditions. Specifically, the ROMP substrate norbornene
(5-Norbornene-2-carboxylic acid) is conjugated to the exterior of a loaded P22
nanocontainer and Grubbs II Catalyst is used to trigger the polymerization reaction leading
to nanocontainer disassembly. Our results demonstrate initial attempts to characterize the
ROMP-triggered release of cargo peptides from P22 nanocontainers. This work provides
proof-of-concept for the construction of a triggerable peptide drug delivery system using
viral nanocontainers.
Keywords: peptide therapeutics; nanocontainers; drug delivery; P22 bacteriophage; viral
capsid; ROMP; controlled disassembly; triggered release; Grubbs catalyst; venom peptides

1. Introduction
For much of the twentieth century, “drug discovery and development” was synonymous with the
identification and synthesis of biologically active small molecules derived from natural products or
created through rational-design processes. However, since 1980 the number of new chemical entities
(NCEs) registered each year with the FDA has remained more or less constant, despite the
proliferation of newly identified drug targets and the considerable financial and scientific resources
devoted to drug discovery [1,2]. Bioactive peptides, which are very potent, highly selective, and do not
produce toxic metabolites upon degradation, are a promising alternative to small molecules for drug
discovery and development [1,3]. There are numerous natural reservoirs of bioactive peptides, such as
the venom arsenal of predatory marine snails, spiders, and other organisms, that have yet to be
thoroughly explored and characterized [4–8]. Ziconotide (Prialt®), a peptide drug first identified in the
venom of the marine snail Conus magus, is the first non-opioid analgesic and is currently used to
alleviate chronic pain in HIV and cancer patients [8–10].
The primary obstacle to the widespread use of bioactive peptides has been their unfavorable
pharmacokinetic profile. Unstructured peptides are degraded by endogenous proteases and are thus
relatively unstable in vivo [11]. Additionally, most peptides, with the exception of specialized
cell-penetrating peptides, cannot cross the blood-brain barrier (BBB) [12]. However, peptide
therapeutics derived from venomous organisms exhibit improved pharmacokinetic profiles, in part due
to the structural integrity provided by disulfide bonds. Ziconotide, for example, is stabilized by three
disulfide bonds that confer increased resistance to endogenous proteases. The structural stability of
ziconotide ensures prolonged relief when it is administered as a pain therapy [8–10]. However,
ziconotide does not cross the BBB, and must be administered by intrathecal injection [10].
An alternative to intrathecal injection for the administration of ziconotide, in which the peptide was
encapsulated in a viral nanocontainer and delivered across the BBB via a trojan horse strategy, was
recently described [12].
Packaging peptides in a nanocontainer delivery system is an effective strategy for improving their
pharmacokinetic profile, as the nanocontainer can protect the peptide during transport and release at
the site of its molecular target. The list of macromolecules that have been investigated for their potential
as delivery vectors is extensive and diverse. It includes polymeric nanoparticles [13], micelles [14],
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liposomes [15], DNA origami structures [16], and protein cages such as viral capsids (with the
infectious genome removed) and ferritins [17,18]. Regardless of the type of macromolecule used,
nanocontainer delivery systems generally consist of three steps: packaging of the pharmacological
agent, targeting of the loaded nanocontainer to the appropriate site in vivo, and disassembly or release
of the active compound. While strategies for packaging and targeting nanocontainers have been
extensively studied, controlled release of the encapsulated drug remains problematic [12,19,20].
In large part, hurdles to nanocontainer disassembly persist because the release mechanism needs to
function under physiological conditions of moderate temperature, neutral pH, and aqueous environment.
Here, we present a strategy for inducing disassembly of a nanocontainer derived from the viral
capsid of the Salmonella typhimurium bacteriophage P22 under physiological conditions. The P22
capsid is a T = 7 icosahedral lattice composed of 420 copies of P22 coat protein (CP) that
self-assemble in the presence of approximately 300 copies of the P22 scaffold protein (SP) [21].
A truncated version of the SP, consisting of the last 66 C-terminal residues, is sufficient for
self-assembly of the procapsid [22]. The Douglas group recently developed a system for packaging
arbitrary gene products into the P22 capsid shell by using standard recombinant methods to create a
fusion protein consisting of an arbitrary cargo protein joined to the P22-SP C-terminus by a thrombin
cleavage site [23]. Various gene products have been loaded into the P22 capsid in this manner,
including the fluorescent proteins EGFP and mCherry, the enzyme alcohol dehydrogenase D,
and ziconotide [12,23,24].

Figure 1. Creating a dissociative viral nanocontainer for peptide drug delivery. A viral
nanocontainer is conjugated to strained olefins that undergo a ring opening polymerization
reaction (ROMP) in the presence of Grubbs II Catalyst. The ROMP reaction disrupts the
architecture of the nanocontainer, resulting in disassembly and release of the encapsulated
peptide cargo.
Our strategy for triggered disassembly of the P22 nanocontainer employs Ring Opening Metathesis
Polymerization (ROMP), an olefin metathesis reaction that is known to proceed under physiological
conditions in the presence of a ruthenium catalyst (Grubbs Catalyst) [25,26]. The ROMP disassembly
strategy is desirable as it can be triggered to release the cargo in response to a defined stimulus,
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which will provide temporal control over the pharmacokinetics of the encapsulated drug [27].
Specifically, we conjugated the ROMP substrate norbornene (5-Norbornene-2-carboxylic acid) to the
exterior of loaded P22 nanocontainers and used a 2nd Generation Grubbs Catalyst (Grubbs II catalyst)
to trigger the ROMP reaction. Our results indicate that the ROMP reaction disrupts the P22
nanocontainer architecture, which could lead to release of the encapsulated cargo (Figure 1).
2. Materials and Methods
2.1. Construction of P22-GFP Nanocontainers
P22-GFP nanocontainers were constructed as described in O’Neil et al. [23] (Figure 2A). Briefly,
BL21 E. coli were transformed with a plasmid containing the genes for the P22 coat protein and an
engineered GFP-scaffold protein fusion. Transformed E. coli were grown to OD600 = 0.6 and induced
with isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were harvested and lysed, and clarified
lysates were subject to ultracentrifugation over a 35% sucrose cushion. Viral pellets were further
purified over a sephacryl (S-500) size-exclusion column (GE Healthcare). Detection of GFP protein
was achieved by electrospray ionization mass spectrometry (45,515 Da for EGFP-SP141 fusions) to
confirm successful encapsulation inside P22 nanocontainers.

Figure 2. Construction of the P22-GFP Nanocontainer. (A) Incorporation of cargo protein
into P22 capsid. When the P22 coat protein (green circles) is co-expressed with an
engineered scaffold protein-cargo protein construct (orange squares and purple circles,
respectively), the nanocontainer self-assembles with the coat protein on the exterior and the
scaffold and fusion proteins on the interior. Here, the cargo protein is GFP. (B) Dynamic
Light Scattering (DLS) of unconjugated P22-GFP nanocontainers reveals spherical entities
with a mean diameter of 49.8 nm. (C) TEM (Transmission Electron Microscopy) image of
P22 nanocontainers. The assembled capsids are homogeneous in size, shape, and packaging.
Scale bar = 100 nm. (D) Confocal fluorescence microscope image of P22-GFP at 100×
magnification confirms the presence of GFP.
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2.2. Confocal Fluorescence Microscopy Characterization of P22-GFP Nanocontainers
Spinning disc confocal microscopy was carried out on a Perkin Elmer UltraView ERS instrument
using a GFP filter. Samples of P22-GFP were diluted 16x with nanopure water, mounted onto a slide,
and examined at 100× magnification. Images were produced with Volocity 3D Image analysis software.
2.3. Conjugation of Norbornene to P22-GFP Nanocontainers
To conjugate norbornene to surface-exposed lysine residues on the P22 bacteriophage capsid,
1.4 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 1.6 mg N-hydroxysuccinimide
(sulfo-NHS) were added to 1 mL of a (1 mg/mL) solution of 5-norbornene-2-carboxylic acid in 0.1M
phosphate buffer (pH 6.0) (all reagents were purchased from Sigma-Aldrich). The solution was
allowed to react at room temperature with intermittent vortexing. After 30 minutes, 0.1 M dibasic
phosphate stock was added dropwise to raise the pH to 7.5. To this activated 5-Norbornene-2-carboxylic
acid solution was added 250 μL of (13.2 mg/mL) P22-GFP in PBS. After reacting at room temperature
overnight on a shaker at 250 rpm, the product was concentrated by means of a 10 KDa MWCO
centrifugal filter device (Amplicon) and resuspended in pH 7.0 phosphate buffer.
2.4. MS Characterization of P22-GFP-Norbornene Nanocontainers
Mass Spectrometry (MS) analyses were carried out on a 6520 Accurate Mass QTOF LC/MS system
(Agilent Technologies). P22 nanocontainers conjugated with 5-Norbornene-2-carboxylic acid (1 μL,
1.0 mg/mL) were injected into an Agilent Eclipse Plus C18 column and eluted with 99.9% ACN, 0.1%
formic acid. Spectra were produced using Agilent MassHunter Qualitative Analysis software.
2.5. Ring Opening Metathesis Polymerization (ROMP) of P22-GFP-Norbornene Nanocontainers
Two samples of (2 mg/mL) P22-GFP-Norbornene were transferred to microfuge tubes in aliquots of
20 μL. To the first (control) sample was added 1.7 μL of nanopure H2O. To the second (experimental)
sample was added 1.7 μL of 0.01% (w/v) (10 mol%) Grubbs II Catalyst (Sigma-Aldrich). Samples
were vortexed and allowed to react 24 hours at room temperature.
2.6. Transmission Electron Microscopy (TEM) Characterization of P22-GFP Nanocontainers and
Post-ROMP P22-GFP-Norbornene Nanocontainers
TEM images were produced on a JEOL JEM 2100 instrument with an acceleration voltage of
200 kV. Samples were applied to a carbon-coated copper grid and stained with uranyl acetate solution,
then dried at room temperature. Images were processed and analyzed using ImageJ software.
2.7. DLS Characterization of P22-GFP Nanocontainers
Dynamic light scattering (DLS) measurements were recorded using a PD2000DLS instrument
(PDDLS/Cool Batch 90T, Precision Detectors). Nanocontainers at a concentration of 1 mg/mL in pH 7.2
PBS were filtered through a 0.2 μm syringe filter and transferred to a 0.5 × 0.5 mm glass cuvette for
DLS analysis.
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2.8. P22-GFP Heat-Activated Disassembly Monitored by Native Agarose Gels
P22-GFP-Norbornene samples were divided into eight aliquots of 15 μL each and heated for
10 minutes under a thermal gradient. Specifically, the first aliquot was heated at 50 °C, with 5 degrees
added for each subsequent aliquot, so that the final aliquot was heated at 85 °C. Samples were allowed
to cool, mixed with loading buffer (40% glycerol, bromophenol blue) and loaded into the wells of a
1.0% native agarose gel with unheated P22-GFP and P22-GFP-Norborne controls. Gels were run at 65 V
for 2.5 hours in TAE buffer (40 mM tris, 20 mM acetic acid, 1 mM EDTA), then stained with
coomassie blue and destained with acetic acid and methanol. Images were produced using a
Foto/Analyst FX imaging system (Fotodyne).
3. Results
3.1. Characterization of P22-GFP Nanocontainers
The integrity of P22-GFP nanocontainers was determined using dynamic light scattering (DLS),
TEM, and spinning disk confocal fluorescence microscopy. DLS analysis detected spherical
nanocontainers with a mean diameter of 49.8 nm (expected mean diameter 50.0 nm) [23]. TEM
images revealed capsids that are homogeneous in size and shape (Figure 2B and 2C). Spinning disk
confocal fluorescence microscopy at 100× magnification and 16× dilution revealed a field of bright
green dots, indicating the successful encapsulation of GFP. DLS, TEM, and confocal fluorescence
microscopy characterization, together with prior MS data [23] confirmed the construction of P22-GFP
nanocontainers.
3.2. Characterization of Norbornene-Conjugated P22-GFP Nanocontainers
The P22-GFP-norbornene conjugation reaction was monitored by MS analysis. Compounds with
masses corresponding to that of the P22 coat protein (expected mass 46,596 Da, observed mass 47,192 Da)
plus an integral number (between 2 and 6) of 120 Da adducts was detected (Table 1). The 120 Da mass
corresponds to a 5-norbornene-2-carboxylic acid moiety conjugated to a free amine to form an amide
bond (Figure 3). A weighted average of the number of norbornene adducts per coat protein monomer
(with the weight determined by the relative abundance by volume of each compound cited in
Table 1) suggests there are slightly more than four norbornene moieties per coat protein monomer,
or approximately (4 norbornene adducts per monomer) × (420 coat protein monomers per
nanocontainer) equates to 1700 norbornenes per nanocontainer. Although the P22 coat protein
contains 19 lysine residues that could potentially couple with an activated 5-Norbornene-2-carboxylic
ester, not all of these are surface-exposed, which would explain why not all 19 lysines are conjugated
with norbornene.
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Table 1. Compounds detected through MS analysis of norbornene-conjugated P22-GFP
nanocontainers. Seven P22-Norbornene compounds were detected by MS analyses.
The unconjugated coat protein had a baseline observed mass of 47,192 Da
(expected mass = 46,596 Da). Each additional conjugated norbornene adds an average of
120 Da. to the baseline mass. The volume-weighted average is 4.12 norbornenes per coat
protein monomer.
Compound
5
4
3
2
6
1
7

Mass
47,792.2998
47,672.4353
47,552.3638
47,672.0044
47,911.832
47,432.2401
47,911.4899

Vol %
26.8
24.17
20.9
12.43
5.81
5.24
3.95

No. of Norbornenes
5
4
3
4
6
2
6

Figure 3. Conjugation of Norbornene-COOH to the Capsid Surface. (A) Norbornene-COOH
is activated with EDC and sulfo-NHS, leading to the formation of an amide bond with the
ε-NH2 of surface-exposed lysine residues. (B) Mass spectrum of unmodified capsid coat
protein (m/z = 47,192). (C) Mass spectrum of coat protein subunit conjugated with five
norbornene subunits (m/z = 47,792).
3.3. TEM Characterization of P22-GFP-Norbornene ROMP Reaction
The integrity of the P22 nanocontainers before and after conjugation with norbornene and treatment
with Grubbs II catalyst was monitored by TEM. TEM revealed that P22-GFP-Norbornene capsids
treated with 10 mol% Grubbs II catalyst exhibited strained and distorted morphologies when compared
with untreated P22-GFP-Norbornene (Figure 4). Treated capsids also exhibited robust bridge
structures at inter-capsid interfaces. The ROMP reaction was functional under experimental conditions.
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Figure 4. Disassembly of P22 nanocontainer using Grubbs Catalyst-activated ROMP.
(A) Reaction scheme of ROMP (Ring Opening Metathesis Polymerization) reaction. P22
nanocontainers conjugated with norbornene are treated at room temperature under
physiological conditions with Grubbs II Catalyst, which triggers polymerization of
norbornene and disruption of nanocontainer conformation. TEM of nanocontainers before
ROMP reaction (B), and after ROMP (C), illustrate the morphological change.
P22-norbornene nanocontainers treated with 10 mol% Grubbs II catalyst exhibit strained
and distorted morphologies when compared with untreated P22-GFP-Norbornene
nanocontainers. Treated nanocontainers also exhibit robust bridge structures, suggesting
that the ROMP reaction is occurring at both intra- and inter-nanocontainer interfaces.
Scale bar = 50 nm.
3.4. Characterization of Heat-Induced Dissociation of P22 Nanocontainer
P22 nanocontainers are known to undergo morphogenesis when heated. The nanocontainers expand
to a diameter of 64 nm when heated at 65 °C and shed the coat protein pentons at each of the 12 fivefold
axes of symmetry when heated at 75 °C. Heating above these temperatures causes disassembly [23,28].
Native agarose gel characterization illustrated that P22-GFP-Norbornene nanocontainers begin to
dissociate after 10 minutes in the 60–70 °C range, as indicated by the disappearance of the 30 MDa band
(Figure 5). The streaking towards the top of the gel in lanes, corresponding to temperatures of
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65 °C and above, is likely due to the formation of large amorphous aggregates, which are visible in the
background of TEM images of samples of P22-GFP-Norbornene heated for 10 minutes at 65 °C
(Figure 5A). Significantly, TEM images of P22-GFP-Norbornene treated with 10 mol% Grubbs II
catalyst and TEM images of P22-GFP-Norbornene heated for 10 minutes at 65 °C show similar
patterns of morphological distortion, suggesting dissociation of the nanocontainers (Figure 5A).

Figure 5. Heat-induced disassembly of P22 nanocontainers vs. ROMP-triggered
morphological distortion of P22-GFP-norbornene nanocontainers. (A) Heating of P22-GFP
nanocontainers at 65 °C for 10 m results in a rough, distorted texture that indicates the
beginning of capsid dissolution. P22-GFP-Norb nanocontainers treated with 10 mol%
Grubbs II catalyst exhibit a similar pattern of distortion. (B) Native 1% agarose gel of
heated P22-GFP-Norb nanocontainers shows the onset of disassembly after 10 m at 65 °C.
All TEM images at 20k magnification.
4. Conclusions
Delivering peptide drugs to their site of action in a controlled manner remains a significant
challenge. Here we describe a drug delivery system that encapsulates a peptide cargo within a viral
nanocontainer and employs a catalyst-driven ROMP reaction to trigger release of the encapsulated
cargo. Specifically, activated 5-Norbornene-2-carboxylic acid was conjugated to surface-exposed
lysine residues on the P22 bacteriophage procapsid in a yield of approximately four norbornene
moieties per P22 coat protein monomer. Treatment of the P22-GFP-Norbornene nanocontainer with
Grubbs II catalyst precipitated a ROMP reaction that distorts the morphologies of individual
nanocontainers. These results illustrate a method for inducing conformational changes in engineered
P22 bacteriophage nanocontainers that will enable the controlled release of loaded peptide cargos.
Recent studies have illustrated that viral capsid nanoplatforms, such as the P22 capsid used in this
study, are not toxic in cell lines, nor when administered to mice [12,29]. In particular, the Kaiser et al.
study provided a baseline for protein nanoplatform degradation and clearance in vivo. The Kaiser study
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found that single injections of naïve and immunized mice with representative protein cage nanoplatforms
derived from the Cowpea chlorotic mottle virus (CCMV) and the heat shock protein (Hsp) of the
hyperthermophilic archaeon Methanococcus jannaschii did not lead to overt toxicity. Protein cages
were broadly distributed throughout most tissues and organs, were rapidly excreted within 24 hours,
and did not exhibit long-term persistence in tissue or organs. While a comprehensive analysis has yet
to be performed on the P22 capsid, these results suggest that the protein cage of P22 capsid may also
be safe for biomedical applications. In addition, preliminary reports indicate that the polynorbornene
produced by the ROMP disassembly reaction is not cytotoxic [30].
The Grubbs catalyzed ROMP strategy for nanocontainer disassembly that we have pursued here is
novel. Previous strategies for nanocontainer disassembly have required the manipulation of environmental
conditions such as pH and temperature that cannot be readily controlled in vivo [11]. Our ROMP-based
method builds upon the resurgence in material and natural product chemistry applications that
followed the introduction of solvent-tolerable catalysts such as the ruthenium-based Grubbs catalyst in
the 1990s and 2000s. The Grubbs catalyst not only accelerated metathesis reactions to a physiologically
relevant timescale (in many cases a matter of minutes), but also allowed for the use of water-based
solvents and proved effective at initiating metathesis reactions in minimal concentrations [31]. In addition,
the water-compatible properties of the ROMP reaction suggests that the catalyst could be administered
to patients via intravenous drip therapy, similar to saline.
While we have successfully demonstrated the ROMP reaction, there are several questions that need
to be addressed to make this a viable method in vivo. For example, the Grubbs II catalyst applied is
ruthenium-based, and ruthenium (Ru) is mildly toxic [32,33]. However, the amount of Grubbs II
catalyst needed to initiate a ROMP reaction is relatively small. Here we applied 10 mol% Grubbs II
catalyst, however, other studies report effective catalysis in water with amounts as low as 2 mol% [34].
Additionally, there have been efforts to produce ROMP catalysts based on elements with reduced
toxicity, such as molybdenum (Mo) and tungsten (W) [35,36]. Replacing Ru with Mo or W would
extend the potential application of in vivo ROMP nanocontainer dissociation.
Finally, more recent iterations of ROMP catalysts allow for photoactivated reactions that are initiated
when ROMP monomers are exposed to UV-visible light (~365–420 nm) in the presence of a photolabile
catalyst [37]. One recent study used light at similar wavelengths (380–500 nm) to trigger a photoswitchable
affinity tag targeting potassium channels in cultured cerebral cells. Results from the same study indicated
that brain tissue did not significantly impede light penetration using 380–500 nm [38]. An alternative
strategy for triggering a photoactivated ROMP reaction within the CNS would be to use a red-shifted
photoswitchable catalyst, since near-IR radiation can more effectively penetrate tissue. Photoactivated
ROMP could thus provide a trigger mechanism for exerting precise spatial and temporal control over
the release of encapsulated drug cargoes. Together with our findings, these recent studies pave the way
for the development of a ROMP-triggered P22-based nanocontainer system for the controlled delivery
of peptide therapeutics.
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